ArticleCureus2025
Macrophage Activation Syndrome as an Atypical Manifestation of Mixed Connective Tissue Disease in a 14-Year-Old Girl: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophage activation syndrome (MAS) is a subtype of secondary hemophagocytic lymphohistiocytosis (HLH) associated with rheumatic diseases. It is a life-threatening condition characterized by hypercytokinemia due to uncontrolled T-cell and macrophage activation. MAS is an uncommon complication in patients with mixed connective tissue disease (MCTD), particularly in those without a prior diagnosis or treatment. We report the case of a previously healthy 14-year-old Japanese girl admitted to our hospital with severe headache and persistent fever. Despite an initially unremarkable examination, she subsequently developed altered mental status, arthralgia, and a small erythema. Laboratory findings revealed cytopenia and coagulation abnormalities, along with elevated levels of C-reactive protein, liver enzymes, triglycerides, and ferritin. Although she did not meet the HLH-2004 diagnostic criteria established by the Histiocyte Society, MAS was suspected based on early diagnostic criteria for MAS associated with other rheumatic diseases. Prompt initiation of steroid pulse therapy led to rapid clinical improvement. Further serological testing revealed strongly positive anti-U1-ribonucleoprotein (RNP) antibodies, confirming a diagnosis of MCTD. Over one year of follow-up, the patient remained well-controlled on a tapered dose of prednisolone, with no serological relapse. This case highlights the importance of early diagnosis and treatment of MAS, even when the underlying disease is unknown. Additionally, cytokine profiling may provide valuable insights into understanding the pathogenesis of diseases that cause hypercytokinemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.